In a recent meta-analysis on the expression of PD-1 and PD-L1 in solid tumors, as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors, odds ratios of objective response in PD-L1–positive patients compared with PD-L1–negative patients was 2.34 for RCC and 2.20 for bladder cancer (15). Here, CD274 is linked to renal cell carcinoma.